Foxy-5
Based on 7 publication(s) in Google Scholar
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.02%
- No. CAS: 881188-51-8
- Fòrmula: C26H42N6O12S2
- Peso molecular:694.77
-
Almacenamiento:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Foxy-5
More- Int J Oral Sci. 2024 Feb 19;16(1):15. [Abstract]
- J Neuroinflammation. 2024 Mar 26;21(1):75. [Abstract]
- Phytomedicine. 2025 Feb 10:139:156491. [Abstract]
- Int Immunopharmacol. 2026 Mar 1:172:116168. [Abstract]
- iScience. 2024 Dec 1;27(12):111517. [Abstract]
- Pathol Res Pract. 2024 May 26:259:155369. [Abstract]
- Patent. US20230130144A1.
Actividad biológica
|
Wnt5A |
Foxy-5 (100 μM, 24 h) inhibits the invasion of tumor cells in DU145 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DU145, PC3
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Reduced DU145 cell invasion by 40%.
Foxy-5 (2 mg/kg, intraperitoneal injection, once a day, for 3-9 weeks) significantly reduces the early metastasis and spread of WNT5A low DU145 prostate cancer cells in a mouse model of prostate cancer xenotransplantation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A Xenograft Mouse Model of Human Colonic Cancer[2]
-
Dosage:2 mg/kg
-
Administration:i.p. 9 times a day for 7-23 days
-
Result:Reduced the expression of ALDH, DCLK1 and COX-2.
Increased the expression of 15-PGDH.
Reduced the expression of the downstream β-catenin target ASCL2.
-
Animal Model:A Xenograft Mouse Model of Prostate Cancer [3]
-
Dosage:2 mg/kg
-
Administration:i.p. once a day, for 3-9 weeks
-
Result:Reduced metastatic spread and the number of tumor cells in lymph nodes.
Chemical Information
-
No. CAS 881188-51-8
-
Appearance Solid
-
Peso molecular 694.77
-
Fòrmula C26H42N6O12S2
-
Color White to off-white
-
Sequence
{For}-Met-Asp-Gly-Cys-Glu-Leu
-
Sequence Shortening
{For}-MDGCEL
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Int J Oral Sci
2024 Feb 19;16(1):15. PMID: 38369512 -
J Neuroinflammation
Wnt5a/β-catenin-mediated epithelial-mesenchymal transition: a key driver of subretinal fibrosis in neovascular age-related macular degeneration. [Abstract]2024 Mar 26;21(1):75. PMID: 38532410 -
Phytomedicine
Quercetin improves airway remodeling in COPD rats by suppressing phenotypic switch of ASMCs via inhibiting the Wnt5a/β-catenin pathway. [Abstract]2025 Feb 10:139:156491. PMID: 39955824 -
Int Immunopharmacol
Piezo1 activates Wnt5a/FZD4 signaling to promote osteogenesis and mitigates age-associated bone loss. [Abstract]2026 Mar 1:172:116168. PMID: 41529412 -
iScience
The mesenteric adipokine SFRP5 alleviated intestinal epithelial apoptosis improving barrier dysfunction in Crohn's disease. [Abstract]2024 Dec 1;27(12):111517. PMID: 39759008 -
Pathol Res Pract
PC4 promotes bladder cancer progression and stemness by directly interacting with Sp1 to transcriptionally activate the Wnt5a/β-catenin pathway. [Abstract]2024 May 26:259:155369. PMID: 38820928 -
Solvente y solubilidad
DMSO : ≥ 100 mg/mL (143.93 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Säfholm A, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008 Oct 15;14(20):6556-63. [Content Brief]
[2]. Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. Anticancer Res. 2019 Apr;39(4):1719-1728. [Content Brief]
[3]. Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One. 2017 Sep 8;12(9):e0184418. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4393 mL | 7.1966 mL | 14.3933 mL | 35.9831 mL |
| 5 mM | 0.2879 mL | 1.4393 mL | 2.8787 mL | 7.1966 mL | |
| 10 mM | 0.1439 mL | 0.7197 mL | 1.4393 mL | 3.5983 mL | |
| 15 mM | 0.0960 mL | 0.4798 mL | 0.9596 mL | 2.3989 mL | |
| 20 mM | 0.0720 mL | 0.3598 mL | 0.7197 mL | 1.7992 mL | |
| 25 mM | 0.0576 mL | 0.2879 mL | 0.5757 mL | 1.4393 mL | |
| 30 mM | 0.0480 mL | 0.2399 mL | 0.4798 mL | 1.1994 mL | |
| 40 mM | 0.0360 mL | 0.1799 mL | 0.3598 mL | 0.8996 mL | |
| 50 mM | 0.0288 mL | 0.1439 mL | 0.2879 mL | 0.7197 mL | |
| 60 mM | 0.0240 mL | 0.1199 mL | 0.2399 mL | 0.5997 mL | |
| 80 mM | 0.0180 mL | 0.0900 mL | 0.1799 mL | 0.4498 mL | |
| 100 mM | 0.0144 mL | 0.0720 mL | 0.1439 mL | 0.3598 mL |
Foxy-5 Related Classifications
HY-P1416 Related Classifications
Powered by Bioz